Takeda Pharmaceutical Co Ltd
TAK15.025USD
-0.084-0.56%
Handelsschluss 04/25, 16:00（ET）Kurse um 15 Minuten verzögert
23.82BMarktkapitalisierung
0.11KGV TTM
mehr Informationen über Takeda Pharmaceutical Co Ltd Unternehmen
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Unternehmensinformationen
Unternehmens-codeTAK
Name des UnternehmensTakeda Pharmaceutical Co Ltd
IPO-datumMay 16, 1949
Gegründet am1925
CEOMr. Christophe Weber
Anzahl der mitarbeiter49281
WertpapierartDepository Receipt
GeschäftsjahresendeMay 16
Addresse4F
StadtCHUO-KU
BörseNYSE Consolidated
LandJapan
Postleitzahl103-8668
Telefon81332782111
Websitehttps://www.takeda.com/
Unternehmens-codeTAK
IPO-datumMay 16, 1949
Gegründet am1925
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: JPYUpdate-Zeit: Sun, Apr 6
Währung: JPYUpdate-Zeit: Sun, Apr 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
Nach GeschäftsbereichJPY
Name
Umsatz
Anteil
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
Nach RegionJPY
Name
Umsatz
Anteil
United States
593.84B
51.90%
Europe And Canada (Country)
262.60B
22.95%
Japan
108.34B
9.47%
Asia
69.19B
6.05%
Latin America
58.66B
5.13%
Other
51.53B
4.50%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichJPY
Name
Umsatz
Anteil
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
Aktionäre
Update-Zeit: Tue, Apr 8
Update-Zeit: Tue, Apr 8
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Aktionärsstatistik
Aktionäre
Anteil
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Art
Aktionäre
Anteil
Investment Advisor
1.55%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.27%
Research Firm
0.14%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Other
97.64%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
574
73.02M
2.32%
-10.12M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
2023Q1
627
84.81M
2.73%
-21.74M
2022Q4
637
69.93M
2.25%
-40.01M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Capital Research Global Investors
13.16M
0.42%
+25.31K
+0.19%
Dec 31, 2024
Parametric Portfolio Associates LLC
5.14M
0.16%
+961.51K
+23.02%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.22M
0.13%
-419.02K
-9.04%
Dec 31, 2024
Fidelity Management & Research Company LLC
3.33M
0.11%
+438.69K
+15.18%
Dec 31, 2024
First Trust Advisors L.P.
3.24M
0.1%
+62.72K
+1.97%
Dec 31, 2024
Renaissance Technologies LLC
3.08M
0.1%
-139.40K
-4.33%
Dec 31, 2024
Brandes Investment Partners, L.P.
3.04M
0.1%
-192.02K
-5.94%
Dec 31, 2024
Goldman Sachs Asset Management, L.P.
2.32M
0.07%
+131.24K
+6.01%
Dec 31, 2024
Van Eck Associates Corporation
2.21M
0.07%
+35.19K
+1.62%
Dec 31, 2024
Aperio Group, LLC
2.20M
0.07%
+313.03K
+16.56%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
VanEck Pharmaceutical ETF
4.7%
SGI Enhanced Global Income ETF
3.05%
Roundhill GLP-1 & Weight Loss ETF
2.1%
ActivePassive International Equity ETF
0.6%
First Trust Value Line Dividend Index Fund
0.45%
Pacer Trendpilot International ETF
0.26%
Avantis International Equity ETF
0.07%
Avantis Responsible International Equity ETF
0.07%
DFA Dimensional International Core Equity 2 ETF
0%
Pacer Developed Markets International Cash Cws 100
0%
Mehr Anzeigen
VanEck Pharmaceutical ETF
Anteil4.7%
SGI Enhanced Global Income ETF
Anteil3.05%
Roundhill GLP-1 & Weight Loss ETF
Anteil2.1%
ActivePassive International Equity ETF
Anteil0.6%
First Trust Value Line Dividend Index Fund
Anteil0.45%
Pacer Trendpilot International ETF
Anteil0.26%
Avantis International Equity ETF
Anteil0.07%
Avantis Responsible International Equity ETF
Anteil0.07%
DFA Dimensional International Core Equity 2 ETF
Anteil0%
Pacer Developed Markets International Cash Cws 100
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
1.42T
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten